US Pharma MarketingAgios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Agios Pharmaceuticals’ next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).
Source: FierceBiotech